The Community Guide

- gsearch

Search Results

Narrow Results:

2021 1
2020 2

Journal Article 3

Acetylcholinesterase inhibitors 1
Alzheimer’s disease and related dementias 1
Alzheimer’s disease and related dementiasanticholinergics 1
antimuscarinics 1
bladder 1
disparities 1
donepezil 1
galantamine 1
memantine 1
pharmaco epidemiology 1
rivastigmine 1

1 - 3 of 3 Results

Refine Results

Refine Results:

Alzheimer’s Disease-Related Neuropathology Among Patients with Medication Treated Type 2 Diabetes in a Community-Based Autopsy Cohort

CITE Title : Alzheimer’s Disease-Related Neuropathology Among Patients with Medication Treated Type 2 Diabetes in a Community-Based Autopsy Cohort Personal Author(s) : Barthold, Douglas;Gibbons, Laura E.;Marcum, Zachary A.;Gray, Shelly L.;Keene, C. Dirk;Grabowski, Thomas J.;Postupna, Nadia;Larson, Eric B.;Crane, Paul K.; Published Date : 2021 Source : J Alzheimers Dis. 83(3):1303-1312 URL : https://stacks.cdc.gov/view/cdc/114476 Barthold, Douglas et al. (2021). Alzheimer’s Disease-Related Neuropathology Among Patients with Medication Treated Type 2 Diabetes in a Community-Based Autopsy Cohort. 83(3). Barthold, Douglas et al. "Alzheimer’s Disease-Related Neuropathology Among Patients with Medication Treated Type 2 Diabetes in a Community-Based Autopsy Cohort" 83, no. 3 (2021) Barthold, Douglas et al. "Alzheimer’s Disease-Related Neuropathology Among Patients with Medication Treated Type 2 Diabetes in a Community-Based Autopsy Cohort" vol. 83, no. 3, 2021 Export RIS Citation Information.

:

Barthold, Douglas ;

Gibbons, Laura E.

2021 | J Alzheimers Dis. 83(3):1303-1312

:

Background:Diabetes is a risk factor for Alzheimer’s disease and related dementias (ADRD). Epidemiologic evidence shows an association between diabe...
Alzheimer’s disease and related dementias risk: Comparing users of non-selective and M3-selective bladder antimuscarinic drugs

CITE Title : Alzheimer’s disease and related dementias risk: Comparing users of non-selective and M3-selective bladder antimuscarinic drugs Personal Author(s) : Barthold, Douglas;Marcum, Zachary A.;Gray, Shelly L.;Zissimopoulos, Julie; Published Date : 12 2020;12-2020; Source : Pharmacoepidemiol Drug Saf. 29(12):1650-1658 URL : https://stacks.cdc.gov/view/cdc/101075 Barthold, Douglas et al. (2020). Alzheimer’s disease and related dementias risk: Comparing users of non-selective and M3-selective bladder antimuscarinic drugs. 29(12). Barthold, Douglas et al. "Alzheimer’s disease and related dementias risk: Comparing users of non-selective and M3-selective bladder antimuscarinic drugs" 29, no. 12 (2020) Barthold, Douglas et al. "Alzheimer’s disease and related dementias risk: Comparing users of non-selective and M3-selective bladder antimuscarinic drugs" vol. 29, no. 12, 2020 Export RIS Citation Information.

:

Barthold, Douglas

;

Marcum, Zachary A.

12 2020 | Pharmacoepidemiol Drug Saf. 29(12):1650-1658

:

Purpose:Bladder antimuscarinic (BAM) drug use is associated with increased risk of Alzheimer’s disease and related dementias (ADRD). It is hypothesi...
Pharmaceutical Treatment for Alzheimer’s Disease and Related Dementias: Utilization and Disparities

CITE Title : Pharmaceutical Treatment for Alzheimer’s Disease and Related Dementias: Utilization and Disparities Personal Author(s) : Barthold, Douglas;Joyce, Geoffrey;Ferido, Patricia;Drabo, Emmanuel F.;Marcum, Zachary A.;Gray, Shelly L.;Zissimopoulos, Julie; Published Date : 2020;2020; Source : J Alzheimers Dis. 76(2):579-589 URL : https://stacks.cdc.gov/view/cdc/158037 Barthold, Douglas et al. (2020). Pharmaceutical Treatment for Alzheimer’s Disease and Related Dementias: Utilization and Disparities. 76(2). Barthold, Douglas et al. "Pharmaceutical Treatment for Alzheimer’s Disease and Related Dementias: Utilization and Disparities" 76, no. 2 (2020) Barthold, Douglas et al. "Pharmaceutical Treatment for Alzheimer’s Disease and Related Dementias: Utilization and Disparities" vol. 76, no. 2, 2020 Export RIS Citation Information.

:

Barthold, Douglas ;

Joyce, Geoffrey

2020 | J Alzheimers Dis. 76(2):579-589

:

Background:Four prescription drugs (donepezil, galantamine, memantine, and rivastigmine) are approved by the US FDA to treat symptoms of Alzheimer’s...